| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5618168 | Journal of Vascular Surgery | 2016 | 8 Pages |
Abstract
Both fTEVAR and bTEVAR are feasible for the treatment of aortic arch diseases in high-risk patients. Results are promising, although fTEVAR was associated with higher mortality in this early experience. bTEVAR was more commonly used in Ishimaru zone 0.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Nikolaos MD, PhD, E. Sebastian MD, PhD, Yskert MD, PhD, Sabine MD, PhD, Fiona MD, Christian MD, PhD, Blayne PhD, Tilo MD, PhD,